- Home
- RYN vs OGN Comparison
RYN vs OGN Comparison
Compare RYN & OGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RYN | OGN |
|---|---|---|
| Founded | 1926 | 1923 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.3B | 2.7B |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | RYN | OGN |
|---|---|---|
| Price | $22.03 | $7.02 |
| Analyst Decision | Hold | Hold |
| Analyst Count | 4 | 5 |
| Target Price | ★ $27.25 | $14.10 |
| AVG Volume (30 Days) | 1.4M | ★ 4.9M |
| Earning Date | 02-04-2026 | 11-10-2025 |
| Dividend Yield | ★ 13.23% | 1.12% |
| EPS Growth | ★ 373.89 | N/A |
| EPS | ★ 5.07 | 1.91 |
| Revenue | $1,293,371,000.00 | ★ $6,301,000,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $4.31 | ★ $3.75 |
| Revenue Growth | ★ 60.70 | N/A |
| 52 Week Low | $21.06 | $6.18 |
| 52 Week High | $29.38 | $17.23 |
Technical Indicators
Market Signals| Indicator | RYN | OGN |
|---|---|---|
| Relative Strength Index (RSI) | 48.95 | 41.82 |
| Support Level | $21.59 | $6.90 |
| Resistance Level | $22.85 | $7.49 |
| Average True Range (ATR) | 0.53 | 0.30 |
| MACD | 0.15 | 0.02 |
| Stochastic Oscillator | 50.75 | 12.57 |
Price Performance
Historical ComparisonAbout RYN Rayonier Inc. REIT
Rayonier owns and manages over 2 million acres of timberland in the United States. It is one the largest private landowners in North America. Rayonier is structured as a real estate investment trust and is not required to pay federal income taxes on earnings generated by timber harvest activities.
About OGN Organon & Co.
Organon & Co is a science-based pharmaceutical company that develops and delivers health solutions through a portfolio of prescription therapies within women's health, biosimilars, and established brands. The Company's operations include the following product portfolio: Women's health, Biosimilars and Established medicines. Geographically, it derives a majority of its revenue from Europe and Canada followed by the United States and then Asia Pacific and Japan. The company generates the majority of its revenue from the Established Brands product portfolio.